Holen Sie sich die Stockscreener-App
62.43
8.24%
4.75
Handel nachbörslich:
63.47
1.04
+1.67%
Schlusskurs vom Vortag:
$57.68
Offen:
$57.78
24-Stunden-Volumen:
439.10K
Relative Volume:
0.80
Marktkapitalisierung:
$1.79B
Einnahmen:
$234.60M
Nettoeinkommen (Verlust:
$-13.23M
KGV:
-119.92
EPS:
-0.5206
Netto-Cashflow:
$19.61M
1W Leistung:
+12.71%
1M Leistung:
+12.67%
6M Leistung:
+106.38%
1J Leistung:
+237.28%
1-Tages-Spanne:
$57.55
$63.25
1-Wochen-Bereich:
$54.23
$63.25
52-Wochen-Spanne:
$15.40
$68.39
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
62.43 | 1.66B | 234.60M | -13.23M | 19.61M | -0.5206 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-03-12 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | BTIG Research | Buy |
| 2024-02-21 | Eingeleitet | Stifel | Buy |
| 2024-02-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
Risk On: Will AnaptysBio Inc face regulatory challengesPortfolio Return Summary & AI Powered Market Entry Ideas - baoquankhu1.vn
AnaptysBio (NASDAQ:ANAB) Trading Up 7.6%Still a Buy? - marketbeat.com
Spin-off Imminent At AnaptysBio - sdbj.com
AnaptysBio, Inc. Common Stock When Issued (ANABV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Assessing AnaptysBio (ANAB) Valuation After New US$100 Million Buyback And Cancelled Equity Offerings - Yahoo Finance
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $69 - Moomoo
Director Susannah Gray at AnaptysBio (ANAB) submits initial Form 3 - Stock Titan
ANAB Technical Analysis & Stock Price Forecast - Intellectia AI
Anaptys to spin-off First Tracks Biotherapeutics, announces $100M buyback - msn.com
ANABV|AnaptysBio Ord Shs|| - TradingKey
First Tracks Biotherapeutics to be spun off from AnaptysBio, Nasdaq trading set for April 20 By Investing.com - Investing.com South Africa
First Tracks Biotherapeutics to be spun off from AnaptysBio, Nasdaq trading set for April 20 - investing.com
Insider Selling: AnaptysBio (NASDAQ:ANAB) Director Sells 20,645 Shares of Stock - marketbeat.com
Aug Highlights: Can AnaptysBio Inc grow without external funding2026 Valuation Update & Weekly High Return Stock Forecasts - baoquankhu1.vn
AnaptysBio Insider Sold Shares Worth $1,158,451, According to a Recent SEC Filing - marketscreener.com
ANAB Stock Price, Quote & Chart | ANAPTYSBIO INC (NASDAQ:ANAB) - ChartMill
Director John Schmid Sells 20,645 Shares of AnaptysBio Inc (ANAB) - GuruFocus
Anaptysbio director Schmid sells $1.16 million in stock By Investing.com - Investing.com Canada
[Form 4] ANAPTYSBIO, INC Insider Trading Activity - stocktitan.net
AnaptysBio Director Sold Shares Worth Over $1.1M - TradingView
Aug Volume: Is AnaptysBio Inc stock a good dividend stock2026 Reactions & Smart Money Movement Tracker - baoquankhu1.vn
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Moderate Buy" by Analysts - marketbeat.com
Wedbush Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75 - Moomoo
ANAB: Piper Sandler Raises Price Target to $95.00, Maintains Ove - GuruFocus
ANAB: Piper Sandler Raises Price Target to $95.00, Maintains Overweight Rating | ANAB Stock News - GuruFocus
Piper Sandler Raises AnaptysBio (NASDAQ:ANAB) Price Target to $95.00 - marketbeat.com
Piper Sandler raises AnaptysBio stock price target to $95 from $67 - Investing.com Canada
H.C. Wainwright reiterates Buy on AnaptysBio stock after spinoff news By Investing.com - Investing.com Canada
HC Wainwright & Co. Reiterates Buy Rating on AnaptysBio (ANAB) | - GuruFocus
[144] ANAPTYSBIO, INC SEC Filing - stocktitan.net
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Raises Target Price to $66 - Moomoo
ANAB SEC FilingsAnaptysbio Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update - marketscreener.com
AnaptysBio (NASDAQ:ANAB) Given Buy Rating at HC Wainwright - marketbeat.com
AnaptysBio Insider Sold Shares Worth $1,089,199, According to a Recent SEC Filing - marketscreener.com
AnaptysBio Spin Off Reshapes Risk Profile With New Royalty Focus - Sahm
AnaptysBio (ANAB) price target increased by 21.16% to 79.82 - MSN
Biotech Startup First Tracks Secures $145M in Private Funding - National Today
(ANAB) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
AnaptysBio authorizes $100M stock buyback, plans spin-off By Investing.com - Investing.com Australia
AnaptysBio sets April 20 spin-off date for First Tracks Bio - Investing.com Australia
AnaptysBio (NASDAQ:ANAB) CEO Daniel Faga Sells 17,679 Shares - MarketBeat
AnaptysBio Authorizes $100 Billion Buyback Plan - National Today
AnaptysBio (NASDAQ:ANAB) Board of Directors Authorizes Share Buyback Plan - marketbeat.com
Anaptysbio CEO Faga sells $1.1 million in shares By Investing.com - Investing.com Australia
AnaptysBio spinoff First Tracks Bio raises $80M in placement By Investing.com - Investing.com India
AnaptysBio (NASDAQ: ANAB) CEO gets PSU grant and sells shares for tax - stocktitan.net
Anaptysbio CEO Faga sells $1.1 million in shares - Investing.com
Anaptysbio, Inc. Appoints Susannah Gray to the Board of Directors - marketscreener.com
Anaptysbio, Inc. Announces Managing the Financial Collaborations for Jemperli with Gsk and Imsidolimab with Vanda - MarketScreener
AnaptysBio Board Approves Spin-Off of First Tracks Bio, Repurchase of $100 Million Shares - Moomoo
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):